Drug Discovery World

NOVEMBER 14, 2023

Verve-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. “Of The post Single-course in vivo base editing therapy proven to lower cholesterol appeared first on Drug Discovery World (DDW).

In-Vivo 52

In-Vivo Gene Editing Gene Genome 52

XTalks

OCTOBER 20, 2023

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. As an in vivo therapy, it can edit genes inside the body rather than in cells extracted from patients. ATTR amyloidosis is a rare, progressive and fatal disease.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Bio Pharma Dive

JULY 17, 2023

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

Gene Editing 237

Gene Editing Gene In-Vivo Research 237

BioPharma Reporter

JUNE 13, 2023

Sygnature Discovery has launched an in vivo inflammation model, that the company says is âexciting but only the beginningâ of understanding life-limiting neuroinflammatory conditions.

In-Vivo 52

In-Vivo Development 52

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. The partnership intends to address a 90% failure rate of new therapy candidates in clinical development, which is a key bottleneck of the pharmaceutical industry.

Development 246

Development Drugs In-Vivo Engineer 246

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 257

Gene Editing Gene In-Vivo RNA 257

Pharmaceutical Technology

MAY 5, 2023

TFF Pharmaceuticals and the National Institute of Environmental Health Sciences (NIEHS) have signed an agreement for the development of dry powder formulations of high molecular weight hyaluronan (HMW-HA) for respiratory diseases.

Development 162

Development In-Vivo In-Vitro Engineer 162

Pharmaceutical Technology

NOVEMBER 9, 2022

ProPhase Labs’ wholly owned subsidiary ProPhase BioPharma has entered a two-year collaboration agreement with Dana-Farber Cancer Institute for further research and development of Linebacker-1 (LB-1). LB-1 will be given along with chemotherapy agents in-vitro, in various cell lines, and in-vivo subcutaneous mouse tumour models in the project.

In-Vivo 130

In-Vivo Development In-Vitro Scientist 130

BioTech 365

NOVEMBER 9, 2020

LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo London, 9 November 2020 ­–LIfT BioSciences, a biotech company developing (..)

In-Vivo 52

In-Vivo Development 52

Pharmaceutical Technology

MARCH 24, 2023

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. The collaboration aims to expand each company’s platform application through the development of new nucleic acid therapeutics, and to expedite their respective non-viral genetic medicines pipelines.

Genetics 130

Genetics Medicine Development In-Vivo 130

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

Drug Discovery World

JANUARY 5, 2024

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. In non-human primate studies, the therapy has demonstrated effective, durable, and well tolerated in vivo CAR-T cell generation.

In-Vivo 52

In-Vivo Development Licensing Licensing 52

Pharmaceutical Technology

SEPTEMBER 29, 2022

Scribe Therapeutics and Sanofi have signed a strategic partnership to expedite the development of breakthrough clustered regularly interspaced short palindromic repeats (CRISPR)-based cell therapies for cancer. Scribe is also entitled to receive potential payments worth over $1bn on meeting development and commercial milestones.

Development 130

Development In-Vivo Genome Genomics 130

Drug Discovery World

APRIL 24, 2024

Evotec will identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the programme towards the selection of a clinical development candidate(s) using its R&D platform.

Development 52

Development In-Vivo In-Vitro Genome 52

Pharmaceutical Technology

OCTOBER 14, 2022

Pharmaceutical companies Xcell Biosciences (Xcellbio) and aCGT Vector have partnered to expedite the development of cell and gene therapies. The two companies will aim to improve the manufacturing and analytic procedures used to develop personalised cell and gene therapies to treat cancer patients.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. MT-302 is a TROP2-targeting in vivo chimeric antigen receptor (CAR) that has been designed to express in the myeloid compartment.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

BioSpace

OCTOBER 21, 2021

The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.

In-Vivo 98

In-Vivo Drugs Development 98

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. of hyponatremia, or low blood sodium levels. In October, the U.S.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

MARCH 16, 2023

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge. Under the collaboration, Libera Bio and Talem Therapeutics will together develop new antibodies for use with MPN delivery.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Moderna will also assume further development, manufacturing, and commercialisation responsibilities on exercising a target option.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Pharmaceutical Technology

MAY 12, 2023

The in vivo study, conducted in mice, involved a phosphatidylserine-containing nano-formulation of mRNA supplied by BioNTech, distinct from traditional lipid nanocrystals (LNCs). Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”.

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

Drug Discovery World

MAY 9, 2023

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Often overlooked by those who point out the shortcomings of mouse models is that not all PDX models are developed equally.

Development 52

Development Drugs In-Vivo Clinical Trials 52

BioPharma Reporter

NOVEMBER 10, 2022

EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.

In-Vivo 98

In-Vivo RNA Development Research 98

Drug Discovery World

APRIL 2, 2024

A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety ‘ Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. Download now.

Drugs 59

Drugs In-Vivo Development Trials 59

Scienmag

OCTOBER 24, 2021

Therefore, understanding the local invasion mechanism is warranted in developing more effective therapeutic approaches, and identifying markers that predict poor prognosis. Many diagnosed patients relapse, despite radical resection of the primary oral squamous cell carcinoma (OSCC) lesion.

In-Vitro 67

In-Vitro In-Vivo Development 67

Drug Discovery World

SEPTEMBER 14, 2023

Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments that could exceed $1.7 Moderna will lead the clinical development and commercialisation of cancer vaccines and TCER therapeutics resulting from the collaboration.

Development 52

Development Vaccination Vaccine In-Vivo 52

Drug Discovery World

JANUARY 3, 2023

Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany. . Mersana will receive an upfront payment of $30 million.

Antibody 52

Antibody Development Research Drugs 52

Pharmaceutical Technology

APRIL 13, 2023

The company is aiming to refocus its efforts on its core therapeutic areas and current late-stage programmes such as the oral TYK2 inhibitor TAK-279, which is under development for several autoimmune disorders.

Gene Therapy 243

Gene Therapy Marketing Gene In-Vivo 243

BioPharma Reporter

JANUARY 10, 2022

have announced a strategic collaboration and option agreement for the use of Mammothâs CRISPR systems to develop in vivo gene-editing therapies. Bayer AG and Mammoth Biosciences, Inc.,

Gene Editing 96

Gene Editing Gene In-Vivo Development 96

Drug Discovery World

MARCH 1, 2023

The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. Despite these connections, very few biologic therapies have been developed for GPCRs, as they are notoriously challenging to generate antibodies against.

Antibody 52

Antibody Development In-Vivo FDA Approval 52

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. AdBio Partners’ mission is to support founding scientists in the development of new therapeutic approaches,” said Alain Huriez, Managing Partner of AdBio Partners.

Development 52

Development Life Science In-Vivo In-Vitro 52

Drug Discovery World

JUNE 15, 2023

ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.

In-Vivo 52

In-Vivo Drugs Branding Protein 52

Drug Discovery World

APRIL 18, 2023

AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.

In-Vivo 97

In-Vivo Clinical Development Development Drugs 97

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). billion in potential milestones if the project advances through development and onto the market. billion agreement that started in 2020.

Gene Editing 96

Gene Editing In-Vivo Gene Sequencing Gene 96

FDA Law Blog

MARCH 19, 2024

using phantoms, ex vivo animal tissue models, and/or in vivo animal testing), computationally, and/or clinically. When in vivo animal testing is needed, tests should follow good laboratory practices and the animal model should be representative of the intended clinical application.

In-Vivo 59

In-Vivo Marketing Regulation Development 59

Drug Discovery World

MARCH 22, 2024

30m raised for first-in-class in vivo cell reprogramming platform Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The post This week in drug discovery (18-22 March) appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy In-Vivo FDA Approval Drugs 52